Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours